

# Features of telemedicine focusing on predictive cancer diagnosis

Klaus Kayser, Stephan Borkenfeld,  
Amina Djenouni, Bathuyag Sereejav,  
Gian Kayser

**Tissue – based diagnosis**

**Definition & recent approaches**

**Present stage of telemedicine**

**Predictive Diagnosis**

**Definition & Algorithms**




**Applications in Cancer diagnosis**

**Perspectives**



# Definition of tissue based diagnosis





- Tissue based diagnosis is the interpretation of images obtained from the human body at light microscopy and higher magnification in combination with clinical data.
- It includes histology, cytology, molecular biology, cytogenetics, molecular genetics, electron microscopy, and biochemistry images.



**Medical Diagnosis is mainly derived from  
Visual Information**

# Tissue – based diagnosis types

- Classic diagnosis: H&E, PAS, cytoskeleton, organ origin markers
- Prognosis estimation: quantitative immune/ligand histochemistry
- Therapy advises (predictive): gene analysis & receptors.
- Risk estimation (array technique): gene analysis



# Definition / Background


**Telepathology is tissue based diagnosis at a distance, part of telemedicine.**

**Telepathology can serve for**

- Medical diagnosis assistance independent on distance, date, language: frame of laboratory data;
- Use in daily routine, science, education, training;
- Direct transfer of diagnosis to centers of treatment and patients' care.
- Technology: According to social forums (php).


# Workflow of a TMCC tuned for developing countries

Forum (MECES, [www.diagnomx.eu](http://www.diagnomx.eu))





- 
- EPIGENETIC MECHANISMS**  
 are different to genetic (DNA sequence)  
 • DNA methylation  
 • Histone modification  
 • Non-coding RNA
- HEALTHY EPIGENOTIC**  
 • Stable  
 • Subtle  
 • Reversible
- CHROMATIN**  
 DNA + HISTONE PROTEIN
- DNA**  
 • DNA methylation: Methyl groups (CH<sub>3</sub>) are added to DNA, usually at CpG sites, which can silence genes.  
 • Histone modification: Chemical groups (e.g., methyl, acetyl) are added to histone tails, which can either activate or silence genes.  
 • Non-coding RNA: Small RNA molecules can bind to DNA and histones, influencing gene expression.
- GENE**  
 • DNA methylation: Methyl groups (CH<sub>3</sub>) are added to DNA, usually at CpG sites, which can silence genes.  
 • Histone modification: Chemical groups (e.g., methyl, acetyl) are added to histone tails, which can either activate or silence genes.  
 • Non-coding RNA: Small RNA molecules can bind to DNA and histones, influencing gene expression.
- HEALTHY EPIGENOTIC**  
 • Stable  
 • Subtle  
 • Reversible
- CHROMATIN**  
 DNA + HISTONE PROTEIN
- DNA**  
 • DNA methylation: Methyl groups (CH<sub>3</sub>) are added to DNA, usually at CpG sites, which can silence genes.  
 • Histone modification: Chemical groups (e.g., methyl, acetyl) are added to histone tails, which can either activate or silence genes.  
 • Non-coding RNA: Small RNA molecules can bind to DNA and histones, influencing gene expression.
- GENE**  
 • DNA methylation: Methyl groups (CH<sub>3</sub>) are added to DNA, usually at CpG sites, which can silence genes.  
 • Histone modification: Chemical groups (e.g., methyl, acetyl) are added to histone tails, which can either activate or silence genes.  
 • Non-coding RNA: Small RNA molecules can bind to DNA and histones, influencing gene expression.
- HEALTHY EPIGENOTIC**  
 • Stable  
 • Subtle  
 • Reversible
- CHROMATIN**  
 DNA + HISTONE PROTEIN
- DNA**  
 • DNA methylation: Methyl groups (CH<sub>3</sub>) are added to DNA, usually at CpG sites, which can silence genes.  
 • Histone modification: Chemical groups (e.g., methyl, acetyl) are added to histone tails, which can either activate or silence genes.  
 • Non-coding RNA: Small RNA molecules can bind to DNA and histones, influencing gene expression.
- GENE**  
 • DNA methylation: Methyl groups (CH<sub>3</sub>) are added to DNA, usually at CpG sites, which can silence genes.  
 • Histone modification: Chemical groups (e.g., methyl, acetyl) are added to histone tails, which can either activate or silence genes.  
 • Non-coding RNA: Small RNA molecules can bind to DNA and histones, influencing gene expression.




# Tumor cell sociology and syntactic structure analysis

## Definition

Syntactic structure analysis is the measure of any structure by "decomposition" into its basic units.

- The aim is to figure out how the texture of any image is generated.
- Measure: <structural entropy>.



## Entropy calculation

## H & E

## Calretinin

**Shannon's entropy:**

**2.84**

**4.36**

**Texture entropy :**

**6.58**

**6.79**

**No of clusters:**

**23**

**51**

**Total entropy (cluster)**

**14.35**

**19.94**

**Entropy Primitives**




**0.51**

**0.79**


**Structure entropy**

**0.58**


**0.83**







# Example protein - carbohydrate recognition



It is probably a “high order” biological steering mechanism, and important for cell to cell and cell to matrix interactions, thus for

- growth regulation (apoptosis)
- cellular maturation
- organ development
- organ - environment behavior

# Predictive Pathology in human Cancer


- **Aim: to analyze extra- and intracellular pathways of cellular proliferation**
- Provides information on membrane proteins in combination with intracellular pathways (gene expression)
- **Specifies the potential therapy (by adding specific antibodies to cytostatic therapy)**
- **Guides the oncologist**
- **Examples: Her2\_neu breast carcinoma, EGFR lung cancer**

# Algorithms of predictive diagnosis

Surgery, Radiology H&E, IHC	Conventional diagnosis	Tumor extension
IHC, FISH	Membrane receptors (*)	Cellular communication
IHC, PCR, FISH, TMA	Proteins, RNA, miRNA (**)	Intracellular pathways
PCR, RNA, DNA assays	Cancer-related target genes (***)	Gene anomalities


(\*) EGFR, VGFR, etc.; (\*\*) (*BAG1, BRCA1, CDC6, CDK2AP1, ERBB3, FUT3, IL11, LCK, RND3, SH3BGR, WNT3A*); (\*\*\*) raf, myc, EML4,...

# Her2\_neu breast carcinoma / entropy



Score 2+  
Trastuzumab  
therapy ?

FISH  
amplification:  
Her2/neu gene




**Microstages: tumor cells**  
**IHC macrostages:**  
Tumor cells {3+, 2+, 1+, 0}  
Connecting membranes  
{n,M+}, (n=1-4, M = 0 - 3)  
 $\Sigma = 16$

**Microstages: tumor cells**  
**FISH macrostages:**  
Nuclear signals {n, F+}  
n number of neighbors  
(n=1- 4, F = 0 – 3)  
 $\Sigma = 16$



## Results: IHC

Microstages:  $\Sigma$  tumor cells: 320  
M(0+) = 22, M(1+)=66, M(2+)=214,  
M(3+)=38, N = No neighbors  
Entropy: 1.03 Macrostages: 16



	N	1	2	3	4	Entropy
<i>M</i>	0	9	13	0	0	0.58
<i>M</i>	1	28	20	8	10	1.19
<i>M</i>	2	16	68	82	47	1.19
<i>M</i>	3	19	16	3	0	1.09


# Results: FISH

Microstages:  $\Sigma$  tumor cells: 120

FISH(0+)= 8, FISH(1+)=16,


FISH(2+)=46, FISH(3+)=50

Entropy: 1.18      Macrostages: 16



	N	1	2	3	4	Entropy
<i>FISH</i>	0	5	3	0	0	0.35
<i>FISH</i>	1	6	4	6	0	1.66
<i>FISH</i>	2	6	9	17	14	1.13
<i>FISH</i>	3	9	23	13	5	1.23

## Common Approaches for Inhibiting the Epidermal Growth Factor Receptor (EGFR) Axis




GRACE

**Molecular markers – potential EGFR inhibition**

**Extracellular: Erbitux**

**Intracellular: Erlotinib  
Gefitinib.**

**A Progression-free-Survival Population**



**230 Patients with therapy relevant mutation in EGFR-Gene  
Standard-Chemotherapy:  
Carboplatin + Paclitaxel**



**Maemondo et al. NEJM 2010  
362:2380-2388**

# Molecular markers that add to EGFR therapy

- ERCC1 gene product functions in the nucleotide excision repair pathway involved in recombinational DNA repair and in the repair of inter-strand crosslinks, and is required for the repair of DNA
- RRM1 gene encodes one of two non-identical subunits which constitute ribonucleoside-diphosphate reductase that produces deoxyribonucleotides prior to DNA synthesis in dividing cells.




# Molecular marker – ERCC1



**83 Patients with N2-stage confirmed by mediastinoscopy**

# Molecular marker – ERCC1, entropy micro- and macrostages

Hwang Cancer 2008 113:1379-1386



320

$\Sigma$  No cells

160

{0, 30, 210, 80}

{0, 1+, 2+, 3+}

{148, 12, 0, 0}

0.84

Entropy

0.28

$1.67 \pm 0.3$

MST Entropy

$1.43 \pm 0.2$

2.43

$\Sigma$  Entropy macrostages 0.92

# Workflow of a TMCC tuned for predictive diagnosis

Forum (MECES, [www.diagnomx.eu](http://www.diagnomx.eu))

Upload images

Email, SMS; phone  
Video conference

Experts on duty






Relational  
Database

Quality Control



Measurements

Teaching Tools  
Tests



Confirmed Report




External Information



Clients



# Organizing experts: Virtual International Pathology Institute



Pathologists agreed to found a virtual international pathology institute **(VIPI)** to

- organize themselves under the umbrella of the European Society of Pathology (ESP)
- perform consultation & definite diagnosis
- work in an institute – like organization
- Advice for additional tissue examinations
- organize continent – based virtual slide centers in collaboration with industry.



# Conclusions

IT on tissue – based diagnosis starts with conventional morphology & image standards -> **diagnosis**  
& MST entropy (flow) -> **survival**  
Identification of molecular subtypes involved in cellular proliferation (EGFR), etc.. -> **therapy advices**



Quantitative analysis of cellular communication opens new perspectives for „targeted cancer therapy“.

Open Forums (MECES) can steer diagnostic information at different levels between different pathologists and laboratories

# Predictive and Communicative Pathology acts as Pilot in Cancer Therapy

thank you very much for your attention

